The partnership expands DNA Script’s footprint and provides sales and support for the SYNTAX System DNA printer in labs in India
DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has reached a distribution agreement with Premas Life Sciences, India. The partnership expands DNA Script’s footprint and provides sales and support for the SYNTAX System DNA printer in labs in India.
DNA Script CEO and co-founder Thomas Ybert said, “This partnership represents an important step in DNA Script’s global commercial expansion and our commitment to support our Indian customers’ research needs.”
APAC is experiencing significant genomic research growth, spurring an increased demand for synthetic biology tools, including DNA Script’s SYNTAX System. As the world’s first commercial benchtop enzymatic DNA printer, the SYNTAX System gives labs complete control over their oligo production, alleviating the need to wait for deliveries from third-party DNA service providers and dramatically accelerating their research.
Dr Debjani Saha, Assistant General Manager-Marketing at Premas Life Sciences, commented, “Premas is proud to add DNA Script to our niche menu. The synthetic biology space is vibrant and gaining a lot of momentum. With the scope for synthesised oligos in therapeutic applications and the growing focus on personalised medicine, we anticipate a keen interest in SYNTAX. A big advantage of this benchtop product is that you can quickly print customised oligos in-house without being dependent on centralised services providers.”
The SYNTAX System printer is the only commercial DNA manufacturing technology that utilises the power of Enzymatic DNA Synthesis (EDS), which produces synthetic DNA without the toxic reagents and hazardous waste associated with older DNA printing methods. Companies can now iterate in a matter of hours by printing ready-to-use oligos in-house instead of waiting days for outsourced service providers to deliver the DNA needed.
